Effect of glucagon‐like peptide‐1 receptor agonists on renal function: A meta‐analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Effect of glucagon‐like peptide‐1 receptor agonists on renal function: A meta‐analysis of randomized controlled trials

Published:2022-04-02 Issue:8 Volume:88 Page:3566-3576
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Simental‐Mendía Mario¹,Linden‐Torres Enrique²,Sánchez‐García Adriana³,Sahebkar Amirhossein⁴⁵,Simental‐Mendía Luis E.¹^ORCID

Affiliation:

1. Department of Orthopedics and Traumatology Hospital Universitario “Dr. José E. González”, Facultad de Medicina, Universidad Autónoma de Nuevo León Monterrey NL Mexico

2. Unidad de Investigación Biomédica, Delegación Durango, Instituto Mexicano del Seguro Social Mexico

3. Endocrinology Division Hospital Universitario “Dr. José E. González”, Facultad de Medicina, Universidad Autónoma de Nuevo León Monterrey NL Mexico

4. Applied Biomedical Research Center Mashhad University of Medical Sciences Mashhad Iran

5. Biotechnology Research Center, Pharmaceutical Technology Institute Mashhad University of Medical Sciences Mashhad Iran

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15304

Reference40 articles.

1. Chronic kidney disease

2. Chronic Kidney Disease Diagnosis and Management

3. UK Renal Registry 19th Annual Report: Chapter 12 Multisite Dialysis Access Audit in England, Northern Ireland and Wales in 2015 and 2014 PD One Year Follow-up: National and Centre-specific Analyses

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile;Expert Opinion on Drug Safety;2024-05-13

2. Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study;Diabetes, Obesity and Metabolism;2024-03-18